Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
TGF-β receptor maintains CD4 T helper cell identity during chronic viral infections
Gavin M. Lewis, … , Hendrik Streeck, Elina I. Zuniga
Gavin M. Lewis, … , Hendrik Streeck, Elina I. Zuniga
Published September 6, 2016
Citation Information: J Clin Invest. 2016;126(10):3799-3813. https://doi.org/10.1172/JCI87041.
View: Text | PDF
Research Article Immunology

TGF-β receptor maintains CD4 T helper cell identity during chronic viral infections

  • Text
  • PDF
Abstract

Suppression of CD8 and CD4 T cells is a hallmark in chronic viral infections, including hepatitis C and HIV. While multiple pathways are known to inhibit CD8 T cells, the host molecules that restrict CD4 T cell responses are less understood. Here, we used inducible and CD4 T cell–specific deletion of the gene encoding the TGF-β receptor during chronic lymphocytic choriomeningitis virus infection in mice, and determined that TGF-β signaling restricted proliferation and terminal differentiation of antiviral CD4 T cells. TGF-β signaling also inhibited a cytotoxic program that includes granzymes and perforin expression at both early and late stages of infection in vivo and repressed the transcription factor eomesodermin. Overexpression of eomesodermin was sufficient to recapitulate in great part the phenotype of TGF-β receptor–deficient CD4 T cells, while SMAD4 was necessary for CD4 T cell accumulation and differentiation. TGF-β signaling also restricted accumulation and differentiation of CD4 T cells and reduced the expression of cytotoxic molecules in mice and humans infected with other persistent viruses. These data uncovered an eomesodermin-driven CD4 T cell program that is continuously suppressed by TGF-β signaling. During chronic viral infection, this program limits CD4 T cell responses while maintaining CD4 T helper cell identity.

Authors

Gavin M. Lewis, Ellen J. Wehrens, Lara Labarta-Bajo, Hendrik Streeck, Elina I. Zuniga

×

Figure 1

Cell-intrinsic TGFβ-RII signaling limits CD4 T cell proliferation but not prototypical T helper subset differentiation early after chronic LCMV infection.

Options: View larger image (or click on image) Download as PowerPoint
Cell-intrinsic TGFβ-RII signaling limits CD4 T cell proliferation but no...
Reconstituted 1:1 mix of WT (CD45.1, black) and ERCre+ Tgfbr2fl/fl (RIIflox-CD45.2, red) bone marrow–chimeric mice were tamoxifen treated, rested, and infected with 2 × 106 PFU of LCMV Cl13. Blood was analyzed prior to infection (A and B) and spleens, livers, and lungs were analyzed on postinfection day 9 for the presence of LCMV-specific CD4 T cells by flow cytometry (C–J). (A) Surface TGFβ-RII on circulating leukocytes after tamoxifen treatment over isotype staining (gray). (B) CD44 and CD62L activation markers on total CD4 and CD8 T cells. (C) Percentage of PD1+ CD4 T cells after gating on CD4 T cells from each donor compartment in the indicated tissue. (D) Incorporation of 7-aminoactinomycin D (7AAD) and BrdU (left) after a 16-hour pulse in splenic CD4 PD1+ T cells or annexin V staining (right) from either WT or RIIflox compartments. (E) Percentages of virus-specific I-Ab:GP67–77+ cells of CD4 T cells. (F) Coproduction of intracellular IFN-γ and TNF-α, or TNF-α and IL-2 after a 5-hour stimulation of splenocytes with GP67–77 cognate peptide, graphed as percentage of I-Ab:GP67–77+ cells from C. (G) Representative overlays and mean fluorescence intensity (MFI) plotted for TBET expression in CD4 I-Ab:GP61–80 T cells in WT and RIIflox compared with naive CD4 T cells (gray). (H and I) CXCR5 vs. BCL6 (H) and SLAM vs. CXCR5 (I) staining on CD4 I-Ab:GP67–77 T cells. (J) FOXP3 expression in PD1+ CD4 T cells. Representative of 3 independent experiments, with n = 4 or 5 mice/experiment. Paired t test, *P < 0.05, **P < 0.005.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts